Abstract
We evaluated the efficacy and safety of indometacin farnesil (Infree^[○!R]), an anti-in-flammatory analgesic tissue activator, in 21 patients with temporomandibular arthrosis who had the chief complaint of pains. The drug was administered orally at a dose of 200mg (or 100mg depending on the case) twice daily, after meals in the morning and evening, for 2 weeks or more. 1) Spontaneous pain, kinesalgia, tenderness, headache, and tinnitus showed a relatively high rate of improvement. 2) Based on assessments classified as "remarkably improved", "moderately improved" and "slightly improved", the final general improvement rating was 33.3% (7/21), 33.3% (7/21), and 28.6% (6/21), respectively. 3) Nausea was the sole adverse reaction noted in 1 of 21 patients. 4) Based on assessments classified as "very useful", "moderately useful" and "slightly useful", the general utility rating was 23.8%(5/21), 42.9%(9/21), and 23.8%(5/21), respectively. 5) Based on the results presented, indometacin farnesil may be considered as a drug of high utility with a wide margin of safety that alleviates pains in temporomandibular arthrosis.